Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. Among authors: vieitez jm. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
Viéitez JM, Valladares M, Peláez I, de Sande González L, García-Foncillas J, García-López JL, García-Girón C, Reboredo M, Bovio H, Lacave AJ. Viéitez JM, et al. Invest New Drugs. 2011 Oct;29(5):1038-44. doi: 10.1007/s10637-010-9400-z. Epub 2010 Mar 6. Invest New Drugs. 2011. PMID: 20204674 Clinical Trial.
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
Aranda E, Viéitez JM, Gómez-España A, Gil Calle S, Salud-Salvia A, Graña B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, González-Flores E, Salgado Fernández M, Guillén-Ponce C, Garcia-Carbonero R, Safont MJ, La Casta Munoa A, García-Paredes B, López López R, Sastre J, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Aranda E, et al. Among authors: vieitez jm. ESMO Open. 2020 Nov;5(6):e000944. doi: 10.1136/esmoopen-2020-000944. ESMO Open. 2020. PMID: 33148620 Free PMC article. Clinical Trial.
Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer.
Esteban E, Fra J, Corral N, Valle M, Carrasco J, Sala M, Puerta J, Estrada E, Palacio I, Vieitez JM, Buesa JM, Lacave AJ. Esteban E, et al. Among authors: vieitez jm. Invest New Drugs. 2002 Feb;20(1):73-82. doi: 10.1023/a:1014490417342. Invest New Drugs. 2002. PMID: 12003196 Clinical Trial.
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M, Muñiz I, Blay P, Fernandez Y, Vieitez JM, Muriel C, Sanmamed M, Coto PP, Izquierdo M, Estrada E, Lacave AJ. Gonzalez EE, et al. Among authors: vieitez jm. Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13. Invest New Drugs. 2011. PMID: 20464446 Clinical Trial.
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ. Muriel C, et al. Among authors: vieitez jm. Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0. Clin Transl Oncol. 2010. PMID: 20709657
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Among authors: vieitez jm. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
73 results